Head and Neck Squamous Cell Carcinoma Clinical Trials
Head and Neck Squamous Cell Carcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for head and Neck Squamous Cell Carcinoma. Corterve aggregates actively recruiting Head and Neck Squamous Cell Carcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Head and Neck Squamous Cell Carcinoma studies
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNCT06980038PHASE2National Cancer Institute (NCI)Irvine, California
- A Study of IDP-001 in Advanced or Metastatic Solid TumorsNCT07602842PHASE1, PHASE2InduPro, Inc.Los Angeles, California
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentNCT06589804PHASE3National Cancer Institute (NCI)Little Rock, Arkansas
- CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCsNCT07172256PHASE2Yale UniversityNew Haven, Connecticut
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCNCT06239220PHASE2Dana-Farber Cancer InstituteBoston, Massachusetts
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06769698PHASE2Regeneron PharmaceuticalsLos Angeles, California
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyNCT05136196PHASE2National Cancer Institute (NCI)Phoenix, Arizona
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaNCT04671667PHASE2National Cancer Institute (NCI)Birmingham, Alabama
- A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664PHASE1Compass TherapeuticsMargate, Florida
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerNCT07195734PHASE2National Cancer Institute (NCI)Tucson, Arizona
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsNCT03526835PHASE1, PHASE2Merus B.V.La Jolla, California
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069PHASE1Eli Lilly and CompanyDuarte, California
See all 104 recruiting Head and Neck Squamous Cell Carcinoma trials →
Head and Neck Squamous Cell Carcinoma trials by state
Head and Neck Squamous Cell Carcinoma trials by metro
Frequently asked questions
- How do I find recruiting Head and Neck Squamous Cell Carcinoma clinical trials?
- Corterve aggregates actively recruiting Head and Neck Squamous Cell Carcinoma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Head and Neck Squamous Cell Carcinoma clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Head and Neck Squamous Cell Carcinoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.